Functioning and Quality of Life in the Treatment for Adolescents with Depression Study (TADS)

Autor/inn/en	Vitiello, Benedetto; Rohde, Paul; Silva, Susan; Wells, Karen; Casat, Charles; Waslick, Bruce; Simons, Anne; Reinecke, Mark; Weller, Elizabeth; Kratochvil, Christopher; Walkup, John; Pathak, Sanjeev; Robins, Michele; March, John
Titel	Functioning and Quality of Life in the Treatment for Adolescents with Depression Study (TADS)
Quelle	In: Journal of the American Academy of Child and Adolescent Psychiatry, 45 (2006) 12, S.1419-1426 (8 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0890-8567
Schlagwörter	Adolescents; Quality of Life; Depression (Psychology); Therapy; Outcomes of Treatment; Cognitive Restructuring; Behavior Modification; Drug Therapy; Measures (Individuals); Questionnaires; Symptoms (Individual Disorders) + Suchen Sie Ihr Suchwort? Adolescent; Adolescence; Adoleszenz; Jugend; Jugendalter; Jugendlicher; Lebensqualität; Therapie; Behaviour modification; Verhaltensänderung; Messdaten; Fragebogen; Psychiatrische Symptomatik
Abstract	Obective: To test whether 12-week treatment of major depression improved the level of functioning, global health, and quality of life of adolescents. Method: The Treatment for Adolescents With Depression Study was a multisite, randomized clinical trial of fluoxetine, cognitive-behavioral therapy (CBT), their combination (COMB), or clinical management with placebo in 439 adolescents with major depression. Functioning was measured with the Children's Global Assessment Scale (CGAS), global health with the Health of the Nation Outcome Scales for Children and-Adolescents (HoNOSCA), and quality of life with the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q). Random-effects regression models were applied to the data. Results: Compared with placebo, COMB was effective on the CGAS (p less than 0.0001), HoNOSCA (p less than 0.05), and PQ-LES-Q (p less than 0.001), whereas fluoxetine was superior to placebo on the CGAS only (p less than 0.05). COMB was superior to fluoxetine on the CGAS (p less than 0.05) and PQ-LES-Q (p = 0.001). Fluoxetine was superior to CBT on the CGAS (p less than 0.01). CBT monotherapy was not statistically different from the placebo group on any of the measures assessed. Treatment effects were mediated by improvement in depressive symptoms measured on the Child Depression Rating Scale-Revised. Conclusions: The combination of fluoxetine and CBT was effective in improving functioning, global health, and quality of life in depressed adolescents. Fluoxetine monotherapy improved functioning. (Contains 1 figure and 2 tables.) (Author).
Anmerkungen	Lippincott Williams & Wilkins. P.O. Box 1600, Hagerstown, MD 21741. Tel: 800-638-3030; Tel: 301-223-2300; Fax: 301-223-2400; Web site: http://www.lww.com/product/?0890-8567
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10